<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32737989</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Protein kinase inhibitors for amyotrophic lateral sclerosis therapy.</ArticleTitle><Pagination><StartPage>1316</StartPage><EndPage>1335</EndPage><MedlinePgn>1316-1335</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15221</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that causes the progressive loss of motoneurons and, unfortunately, there is no effective treatment for this disease. Interconnecting multiple pathological mechanisms are involved in the neuropathology of this disease, including abnormal aggregation of proteins, neuroinflammation and dysregulation of the ubiquitin proteasome system. Such complex mechanisms, together with the lack of reliable animal models of the disease have hampered the development of drugs for this disease. Protein kinases, a key pharmacological target in several diseases, have been linked to ALS as they play a central role in the pathology of many diseases. Therefore several inhibitors are being currently trailed for clinical proof of concept in ALS patients. In this review, we examine the recent literature on protein kinase inhibitors currently in pharmaceutical development for this diseaseas future therapy for AS together with their involvement in the pathobiology of ALS. LINKED ARTICLES: This article is part of a themed issue on Neurochemistry in Japan. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.6/issuetoc.</AbstractText><CopyrightInformation>&#xa9; 2020 The British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palomo</LastName><ForeName>Valle</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-1473-4086</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nozal</LastName><ForeName>Vanesa</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5260-5683</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Prats</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6385-2628</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3882-6081</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2707-8110</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>B2017/BMD3813</GrantID><Agency>Comunidad de Madrid</Agency><Country/></Grant><Grant><GrantID>LCF/BQ/PR18/11640007</GrantID><Agency>La Caixa Banking Foundation</Agency><Country/></Grant><Grant><GrantID>FPU14-00204</GrantID><Agency>MECD</Agency><Country/></Grant><Grant><GrantID>FPU16/04466</GrantID><Agency>MECD</Agency><Country/></Grant><Grant><GrantID>CIBERNED, CB18/05/00040</GrantID><Agency>ISCiii</Agency><Country/></Grant><Grant><Agency>FEDER</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CK-1d</Keyword><Keyword MajorTopicYN="N">Masitinib</Keyword><Keyword MajorTopicYN="N">Protein kinase inhibitors</Keyword><Keyword MajorTopicYN="N">Rapamycin</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32737989</ArticleId><ArticleId IdType="doi">10.1111/bph.15221</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ackerley, S., Grierson, A. J., Banner, S., Perkinton, M. S., Brownlees, J., Byers, H. L., &#x2026; Miller, C. C. (2004). p38&#x3b1; stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences, 26, 354-364. https://doi.org/10.1016/j.mcn.2004.02.009</Citation></Reference><Reference><Citation>Aggarwal, S. P., Zinman, L., Simpson, E., McKinley, J., Jackson, K. E., Pinto, H., &#x2026; Canadian Amyotrophic Lateral Sclerosis c. (2010). Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurology, 9, 481-488. https://doi.org/10.1016/S1474-4422(10)70068-5</Citation></Reference><Reference><Citation>Ahn, S. W., Kim, J. E., Park, K. S., Choi, W. J., Hong, Y. H., Kim, S. M., &#x2026; Sung, J. J. (2012). The neuroprotective effect of the GSK-3&#x3b2; inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice. Journal of the Neurological Sciences, 320, 1-5. https://doi.org/10.1016/j.jns.2012.05.038</Citation></Reference><Reference><Citation>Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., &#x2026; GTP collaborators. (2019). The concise guide to pharmacology 2019/2020: Nuclear hormones receptors. British Journal of Pharmacology, 176, S229-S246. https://doi.org/10.1111/bph.14748</Citation></Reference><Reference><Citation>Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., &#x2026; GTP collaborators. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752</Citation></Reference><Reference><Citation>Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., et al. (2019). The concise guide to pharmacology 2019/20: Introduction and other protein targets. British Journal of Pharmacology, 176, S1-S20. https://doi.org/10.1111/bph.14747</Citation></Reference><Reference><Citation>Alquezar, C., Salado, I. G., de la Encarnacion, A., Perez, D. I., Moreno, F., Gil, C., &#x2026; Martin-Requero, A. (2016). Targeting TDP-43 phosphorylation by casein kinase-1&#x3b4; inhibitors: A novel strategy for the treatment of frontotemporal dementia. Molecular Neurodegeneration, 11, 36.</Citation></Reference><Reference><Citation>Appert-Collin, A., Hugel, B., Levy, R., Niederhoffer, N., Coupin, G., Lombard, Y., &#x2026; Gies, J. P. (2006). Cyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons. Life Sciences, 79, 484-490. https://doi.org/10.1016/j.lfs.2006.01.032</Citation></Reference><Reference><Citation>Ayala, V., Granado-Serrano, A. B., Cacabelos, D., Naudi, A., Ilieva, E. V., Boada, J., &#x2026; Portero-Otin, M. (2011). Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: Implications in ALS. Acta Neuropathologica, 122, 259-270.</Citation></Reference><Reference><Citation>Bajaj, N. P. (2000). Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1, 319-327. https://doi.org/10.1080/146608200300079563</Citation></Reference><Reference><Citation>Balachandran, S., Roberts, P. C., Brown, L. E., Truong, H., Pattnaik, A. K., Archer, D. R., &amp; Barber, G. N. (2000). Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity, 13, 129-141. https://doi.org/10.1016/S1074-7613(00)00014-5</Citation></Reference><Reference><Citation>Battaini, F. (2001). Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacological Research, 44, 353-361. https://doi.org/10.1006/phrs.2001.0893</Citation></Reference><Reference><Citation>Bissaro, M., Federico, S., Salmaso, V., Sturlese, M., Spalluto, G., &amp; Moro, S. (2018). Targeting protein kinase CK1&#x3b4; with riluzole: Could it be one of the possible missing bricks to interpret its effect in the treatment of ALS from a molecular point of view? ChemMedChem, 13, 2601-2605. https://doi.org/10.1002/cmdc.201800632</Citation></Reference><Reference><Citation>Bowerman, M., Murray, L. M., Boyer, J. G., Anderson, C. L., &amp; Kothary, R. (2012). Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Medicine, 10, 24. https://doi.org/10.1186/1741-7015-10-24</Citation></Reference><Reference><Citation>Caccamo, A., Majumder, S., Deng, J. J., Bai, Y., Thornton, F. B., &amp; Oddo, S. (2009). Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. The Journal of Biological Chemistry, 284, 27416-27424. https://doi.org/10.1074/jbc.M109.031278</Citation></Reference><Reference><Citation>Camerino, G. M., Fonzino, A., Conte, E., De Bellis, M., Mele, A., Liantonio, A., &#x2026; Pierno, S. (2019). Elucidating the contribution of skeletal muscle ion channels to amyotrophic lateral sclerosis in search of new therapeutic options. Scientific Reports, 9, 3185. https://doi.org/10.1038/s41598-019-39676-3</Citation></Reference><Reference><Citation>Chen, S., Liao, Q., Lu, K., Zhou, J., Huang, C., &amp; Bi, F. (2020). Riluzole exhibits no therapeutic efficacy on a transgenic rat model of amyotrophic lateral sclerosis. Current Neurovascular Research. https://doi.org/10.2174/1567202617666200409125227</Citation></Reference><Reference><Citation>Cheng, C. W., Lin, M. J., &amp; Shen, C. K. (2015). Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP. Journal of Neurogenetics, 29, 59-68. https://doi.org/10.3109/01677063.2015.1077832</Citation></Reference><Reference><Citation>Chung, Y. H., Joo, K. M., Lim, H. C., Cho, M. H., Kim, D., Lee, W. B., &amp; Cha, C. I. (2005). Immunohistochemical study on the distribution of phosphorylated extracellular signal-regulated kinase (ERK) in the central nervous system of SOD1G93A transgenic mice. Brain Research, 1050, 203-209. https://doi.org/10.1016/j.brainres.2005.05.060</Citation></Reference><Reference><Citation>Cohen, P., &amp; Alessi, D. R. (2013). Kinase drug discovery-What's next in the field? ACS Chemical Biology, 8, 96-104. https://doi.org/10.1021/cb300610s</Citation></Reference><Reference><Citation>Cortes, J. E., Apperley, J. F., DeAngelo, D. J., Deininger, M. W., Kota, V. K., Rousselot, P., &amp; Gambacorti-Passerini, C. (2018). Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: Expert panel review. Journal of Hematology &amp; Oncology, 11, 143.</Citation></Reference><Reference><Citation>Crawford, T. D., Ndubaku, C. O., Chen, H., Boggs, J. W., Bravo, B. J., DeLaTorre, K., &#x2026; Ye, W. (2014). Discovery of selective 4-amino-pyridopyrimidine inhibitors of MAP 4K4 using fragment-based lead identification and optimization. Journal of Medicinal Chemistry, 57, 3484-3493.</Citation></Reference><Reference><Citation>Cuadrado, A., &amp; Nebreda, A. R. (2010). Mechanisms and functions of p38 MAPK signalling. The Biochemical Journal, 429, 403-417. https://doi.org/10.1042/BJ20100323</Citation></Reference><Reference><Citation>Cui, R., Tuo, M., Li, P., &amp; Zhou, C. (2018). Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: A meta-analysis. Neurological Sciences, 39, 811-820.</Citation></Reference><Reference><Citation>Degterev, A., Ofengeim, D., &amp; Yuan, J. (2019). Targeting RIPK1 for the treatment of human diseases. Proceedings of the National Academy of Sciences of the United States of America, 116, 9714-9722. https://doi.org/10.1073/pnas.1901179116</Citation></Reference><Reference><Citation>Dhariwala, F. A., &amp; Rajadhyaksha, M. S. (2008). An unusual member of the CDK family: CDK5. Cellular and Molecular Neurobiology, 28, 351-369.</Citation></Reference><Reference><Citation>Dobrowolny, G., Martini, M., Scicchitano, B. M., Romanello, V., Boncompagni, S., Nicoletti, C., &#x2026; Musaro, A. (2018). Muscle expression of SOD1(G93A) triggers the dismantlement of neuromuscular junction via PKC-Theta. Antioxidants &amp; Redox Signaling, 28, 1105-1119. https://doi.org/10.1089/ars.2017.7054</Citation></Reference><Reference><Citation>Doscas, M. E., Williamson, A. J., Usha, L., Bogachkov, Y., Rao, G. S., Xiao, F., &#x2026; Xu, X. (2014). Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia, 16, 824-834. https://doi.org/10.1016/j.neo.2014.08.006</Citation></Reference><Reference><Citation>Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Casteran, N., &#x2026; Hermine, O. (2009). Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE, 4, e7258. https://doi.org/10.1371/journal.pone.0007258</Citation></Reference><Reference><Citation>Feng, H. L., Leng, Y., Ma, C. H., Zhang, J., Ren, M., &amp; Chuang, D. M. (2008). Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience, 155, 567-572. https://doi.org/10.1016/j.neuroscience.2008.06.040</Citation></Reference><Reference><Citation>Feng, Y., LoGrasso, P. V., Defert, O., &amp; Li, R. (2016). Rho kinase (ROCK) inhibitors and their therapeutic potential. Journal of Medicinal Chemistry, 59, 2269-2300. https://doi.org/10.1021/acs.jmedchem.5b00683</Citation></Reference><Reference><Citation>Feng, Y., Zhou, L., Sun, X., &amp; Li, Q. (2017). Homeodomain-interacting protein kinase 2 (HIPK2): A promising target for anti-cancer therapies. Oncotarget, 8, 20452-20461. https://doi.org/10.18632/oncotarget.14723</Citation></Reference><Reference><Citation>Fornai, F., Longone, P., Cafaro, L., Kastsiuchenka, O., Ferrucci, M., Manca, M. L., &#x2026; Paparelli, A. (2008). Lithium delays progression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 105, 2052-2057. https://doi.org/10.1073/pnas.0708022105</Citation></Reference><Reference><Citation>Freland, L., &amp; Beaulieu, J. M. (2012). Inhibition of GSK3 by lithium, from single molecules to signaling networks. Frontiers in Molecular Neuroscience, 5, 14.</Citation></Reference><Reference><Citation>Fujisawa, T., Takahashi, M., Tsukamoto, Y., Yamaguchi, N., Nakoji, M., Endo, M., &#x2026; Ichijo, H. (2016). The ASK1-specific inhibitors K811 and K812 prolong survival in a mouse model of amyotrophic lateral sclerosis. Human Molecular Genetics, 25, 245-253. https://doi.org/10.1093/hmg/ddv467</Citation></Reference><Reference><Citation>Gagalo, I., Rusiecka, I., &amp; Kocic, I. (2015). Tyrosine kinase inhibitor as a new therapy for ischemic stroke and other neurologic diseases: Is there any hope for a better outcome? Current Neuropharmacology, 13, 836-844. https://doi.org/10.2174/1570159X13666150518235504</Citation></Reference><Reference><Citation>Gal-Ben-Ari, S., Barrera, I., Ehrlich, M., &amp; Rosenblum, K. (2018). PKR: A kinase to remember. Frontiers in Molecular Neuroscience, 11, 480.</Citation></Reference><Reference><Citation>Gibbs, K. L., Kalmar, B., Rhymes, E. R., Fellows, A. D., Ahmed, M., Whiting, P., &#x2026; Schiavo, G. (2018). Inhibiting p38 MAPK&#x3b1; rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death &amp; Disease, 9, 596. https://doi.org/10.1038/s41419-018-0624-8</Citation></Reference><Reference><Citation>Gonz&#xe1;lez-Mu&#xf1;oz, M., Rodr&#xed;guez-Mahillo, A. I., Gil, C., Mor&#xe1;n, Y., Moneo, I., Mart&#xed;nez, A., &amp; Mora, J. S. (2013). Glycogen synthase kinase-3&#x3b2; expression and phosphorylation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis. Br J Med Med Res, 4, 263-271.</Citation></Reference><Reference><Citation>Grievink, H. W., Heuberger, J., Huang, F., Chaudhary, R., Birkhoff, W. A. J., Tonn, G. R., &#x2026; Groeneveld, G. J. (2020). DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. Clinical Pharmacology and Therapeutics, 107, 406-414. https://doi.org/10.1002/cpt.1615</Citation></Reference><Reference><Citation>Gu, S., Fu, W. Y., Fu, A. K. Y., Tong, E. P. S., Ip, F. C. F., Huang, X., &amp; Ip, N. Y. (2018). Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs. Scientific Reports, 8, 7377.</Citation></Reference><Reference><Citation>G&#xfc;nther, R., Balck, A., Koch, J. C., Nientiedt, T., Sereda, M., Bahr, M., &#x2026; T&#xf6;nges, L. (2017). Rho kinase inhibition with fasudil in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis-symptomatic treatment potential after disease onset. Frontiers in Pharmacology, 8, 17.</Citation></Reference><Reference><Citation>Guo, W., Vandoorne, T., Steyaert, J., Staats, K. A., &amp; Van Den Bosch, L. (2020). The multifaceted role of kinases in amyotrophic lateral sclerosis: Genetic, pathological and therapeutic implications. Brain. https://doi.org/10.1093/brain/awaa1022</Citation></Reference><Reference><Citation>Guo, X., Namekata, K., Kimura, A., Harada, C., &amp; Harada, T. (2017). ASK1 in neurodegeneration. Adv Biol Regul, 66, 63-71. https://doi.org/10.1016/j.jbior.2017.08.003</Citation></Reference><Reference><Citation>Hahn, K. A., Ogilvie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., &#x2026; Hermine, O. (2008). Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine, 22, 1301-1309. https://doi.org/10.1111/j.1939-1676.2008.0190.x</Citation></Reference><Reference><Citation>Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., &#x2026; van den Berg, L. H. (2017). Amyotrophic lateral sclerosis. Nature Reviews. Disease Primers, 3, 17071. https://doi.org/10.1038/nrdp.2017.71</Citation></Reference><Reference><Citation>Harris, P. A., Berger, S. B., Jeong, J. U., Nagilla, R., Bandyopadhyay, D., Campobasso, N., &#x2026; Bertin, J. (2017). Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. Journal of Medicinal Chemistry, 60, 1247-1261.</Citation></Reference><Reference><Citation>Hart, M. P., &amp; Gitler, A. D. (2012). ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. The Journal of Neuroscience, 32, 9133-9142.</Citation></Reference><Reference><Citation>Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y., &#x2026; Akiyama, H. (2008). Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Annals of Neurology, 64, 60-70. https://doi.org/10.1002/ana.21425</Citation></Reference><Reference><Citation>Hidenori Ichijo SM, Nakagawa H, Nakoji M, Osawa T, Shimizu T, &amp; Takahashi M (2012). Patent WO2012011548A1.</Citation></Reference><Reference><Citation>Hu, J. H., Zhang, H., Wagey, R., Krieger, C., &amp; Pelech, S. L. (2003). Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. Journal of Neurochemistry, 85, 432-442. https://doi.org/10.1046/j.1471-4159.2003.01670.x</Citation></Reference><Reference><Citation>Imamura, K., Izumi, Y., Banno, H., Uozumi, R., Morita, S., Egawa, N., &#x2026; Inoue, H. (2019). Induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study: Protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. BMJ Open, 9, e033131. https://doi.org/10.1136/bmjopen-2019-033131</Citation></Reference><Reference><Citation>Imamura, K., Izumi, Y., Watanabe, A., Tsukita, K., Woltjen, K., Yamamoto, T., &#x2026; Inoue, H. (2017). The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Science Translational Medicine, 9, eaaf3962. https://doi.org/10.1126/scitranslmed.aaf3962</Citation></Reference><Reference><Citation>Isakov, N. (2018). Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Seminars in Cancer Biology, 48, 36-52. https://doi.org/10.1016/j.semcancer.2017.04.012</Citation></Reference><Reference><Citation>Ito, Y., Ofengeim, D., Najafov, A., Das, S., Saberi, S., Li, Y., &#x2026; Yuan, J. (2016). RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science, 353, 603-608.</Citation></Reference><Reference><Citation>Jackson, P. K. (2012). TTBK2 kinase: Linking primary cilia and cerebellar ataxias. Cell, 151, 697-699.</Citation></Reference><Reference><Citation>Jaiswal, M. K. (2019). Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Medicinal Research Reviews, 39, 733-748.</Citation></Reference><Reference><Citation>Jo, M., Lee, S., Kim, K., Lee, S., Kim, S. R., &amp; Kim, H. J. (2019). Inhibition of MEK5 suppresses TDP-43 toxicity via the mTOR-independent activation of the autophagy-lysosome pathway. Biochemical and Biophysical Research Communications, 513, 925-932. https://doi.org/10.1016/j.bbrc.2019.04.088</Citation></Reference><Reference><Citation>Kametani, F., Nonaka, T., Suzuki, T., Arai, T., Dohmae, N., Akiyama, H., &amp; Hasegawa, M. (2009). Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochemical and Biophysical Research Communications, 382, 405-409. https://doi.org/10.1016/j.bbrc.2009.03.038</Citation></Reference><Reference><Citation>Kannaiyan, R., &amp; Mahadevan, D. (2018). A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 18, 1249-1270. https://doi.org/10.1080/14737140.2018.1527688</Citation></Reference><Reference><Citation>Kiefer, S. E., Chang, C. J., Kimura, S. R., Gao, M., Xie, D., Zhang, Y., &#x2026; Sheriff, S. (2014). The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor. Acta Crystallogr F Struct Biol Commun, 70, 173-181. https://doi.org/10.1107/S2053230X14000144</Citation></Reference><Reference><Citation>Klein, R. (2009). Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nature Neuroscience, 12, 15-20. https://doi.org/10.1038/nn.2231</Citation></Reference><Reference><Citation>Koch, J. C., Tatenhorst, L., Roser, A. E., Saal, K. A., Tonges, L., &amp; Lingor, P. (2018). ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacology &amp; Therapeutics, 189, 1-21. https://doi.org/10.1016/j.pharmthera.2018.03.008</Citation></Reference><Reference><Citation>Koh, S. H., Kim, Y., Kim, H. Y., Hwang, S., Lee, C. H., &amp; Kim, S. H. (2007). Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Experimental Neurology, 205, 336-346. https://doi.org/10.1016/j.expneurol.2007.03.004</Citation></Reference><Reference><Citation>Korkmaz, O. T., Aytan, N., Carreras, I., Choi, J. K., Kowall, N. W., Jenkins, B. G., &amp; Dedeoglu, A. (2014). 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neuroscience Letters, 566, 286-291.</Citation></Reference><Reference><Citation>Krieger, C., Lanius, R. A., Pelech, S. L., &amp; Shaw, C. A. (1996). Amyotrophic lateral sclerosis: The involvement of intracellular Ca2+ and protein kinase C. Trends in Pharmacological Sciences, 17, 114-120. https://doi.org/10.1016/0165-6147(96)10004-3</Citation></Reference><Reference><Citation>Langeswaran, K., Jeyaraman, J., Babu, R. J., Biswas, A., &amp; Dhurgadevi, K. R. (2019). Identifying dual leucine zipper kinase (DLK) inhibitors using e-pharamacophore screening and molecular docking. Journal of Receptor and Signal Transduction Research, 39, 99-105. https://doi.org/10.1080/10799893.2019.1620776</Citation></Reference><Reference><Citation>Lanuza, M. A., Santafe, M. M., Garcia, N., Besalduch, N., Tomas, M., Obis, T., &#x2026; Tomas, J. (2014). Protein kinase C isoforms at the neuromuscular junction: Localization and specific roles in neurotransmission and development. Journal of Anatomy, 224, 61-73. https://doi.org/10.1111/joa.12106</Citation></Reference><Reference><Citation>LaRocca, T. J., Mariani, A., Watkins, L. R., &amp; Link, C. D. (2019). TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes. Neurobiology of Disease, 132, 104514. https://doi.org/10.1016/j.nbd.2019.104514</Citation></Reference><Reference><Citation>Le Pichon, C. E., Meilandt, W. J., Dominguez, S., Solanoy, H., Lin, H., Ngu, H., &#x2026; Lewcock, J. W. (2017). Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Science Translational Medicine, 9, eaag0394. https://doi.org/10.1126/scitranslmed.aag0394</Citation></Reference><Reference><Citation>Lee, S., Jeon, Y. M., Cha, S. J., Kim, S., Kwon, Y., Jo, M., &#x2026; Kim, H. J. (2019). PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies. Autophagy, 1-17. https://doi.org/10.1080/15548627.2019.1686729</Citation></Reference><Reference><Citation>Li, G., Qi, W., Li, X., Zhao, J., Luo, M., &amp; Chen, J. (2020). Recent advances in c-Jun N-terminal kinase (JNK) inhibitors. Current Medicinal Chemistry, 27. https://doi.org/10.2174/0929867327666200210144114</Citation></Reference><Reference><Citation>Li, M., Yasumura, D., Ma, A. A., Matthes, M. T., Yang, H., Nielson, G., &#x2026; Diamond, M. I. (2013). Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease. PLoS ONE, 8, e56026.</Citation></Reference><Reference><Citation>Li, W., Reeb, A. N., Lin, B., Subramanian, P., Fey, E. E., Knoverek, C. R., &#x2026; Ayala, Y. M. (2017). Heat shock-induced phosphorylation of TAR DNA-binding protein 43 (TDP-43) by MAPK/ERK kinase regulates TDP-43 function. The Journal of Biological Chemistry, 292, 5089-5100.</Citation></Reference><Reference><Citation>Liachko, N. F., McMillan, P. J., Guthrie, C. R., Bird, T. D., Leverenz, J. B., &amp; Kraemer, B. C. (2013). CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Annals of Neurology, 74, 39-52. https://doi.org/10.1002/ana.23870</Citation></Reference><Reference><Citation>Liachko, N. F., McMillan, P. J., Strovas, T. J., Loomis, E., Greenup, L., Murrell, J. R., &#x2026; Kraemer, B. C. (2014). The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genetics, 10, e1004803. https://doi.org/10.1371/journal.pgen.1004803</Citation></Reference><Reference><Citation>Lingor, P., Weber, M., Camu, W., Friede, T., Hilgers, R., Leha, A., &#x2026; Investigators, R.-A. (2019). ROCK-ALS: Protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the Rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis. Frontiers in Neurology, 10, 293. https://doi.org/10.3389/fneur.2019.00293</Citation></Reference><Reference><Citation>Liscic, R. M. (2017). ALS and FTD: Insights into the disease mechanisms and therapeutic targets. European Journal of Pharmacology, 817, 2-6. https://doi.org/10.1016/j.ejphar.2017.10.012</Citation></Reference><Reference><Citation>Lombard, C. K., Davis, A. L., Inukai, T., &amp; Maly, D. J. (2018). Allosteric modulation of JNK docking site interactions with ATP-competitive inhibitors. Biochemistry, 57, 5897-5909. https://doi.org/10.1021/acs.biochem.8b00776</Citation></Reference><Reference><Citation>Lovestone, S., Boada, M., Dubois, B., Hull, M., Rinne, J. O., Huppertz, H. J., &#x2026; investigators A. (2015). A phase II trial of tideglusib in Alzheimer's disease. Journal of Alzheimer's Disease, 45, 75-88. https://doi.org/10.3233/JAD-141959</Citation></Reference><Reference><Citation>Lutz, C. (2018). Mouse models of ALS: Past, present and future. Brain Research, 1693, 1-10. https://doi.org/10.1016/j.brainres.2018.03.024</Citation></Reference><Reference><Citation>Magnuson, B., Ekim, B., &amp; Fingar, D. C. (2012). Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. The Biochemical Journal, 441, 1-21. https://doi.org/10.1042/BJ20110892</Citation></Reference><Reference><Citation>Malumbres, M. (2014). Cyclin-dependent kinases. Genome Biology, 15, 122.</Citation></Reference><Reference><Citation>Mandrioli, J., D'Amico, R., Zucchi, E., Gessani, A., Fini, N., Fasano, A., &#x2026; Group R-Ai. (2018). Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore), 97, e11119. https://doi.org/10.1097/MD.0000000000011119</Citation></Reference><Reference><Citation>Marech, I., Patruno, R., Zizzo, N., Gadaleta, C., Introna, M., Zito, A. F., &#x2026; Ranieri, G. (2014). Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Critical Reviews in Oncology/Hematology, 91, 98-111.</Citation></Reference><Reference><Citation>Martinez A, Perez DI, Gil C, Martin-Requero A, Rojas Prats E, Martinez-Gonzalez L, &amp; Perez C (2018). Patent WO2018172587A1.</Citation></Reference><Reference><Citation>Martinez-Gonzalez L, Porras G, Gil C, Palomo V, De Lago E, Gonzalo Consuegra C, &#x2026; Martinez A (2019). Tideglusib, a drug candidate for the treatment of ALS. European Network to Cure ALS (ENCALS) meeting.</Citation></Reference><Reference><Citation>Martinez-Gonzalez, L., Rodriguez-Cueto, C., Cabezudo, D., Bartolome, F., Andres-Benito, P., Ferrer, I., &#x2026; de Lago, E. (2020). Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1&#x3b4; kinase inhibitor treatment. Scientific Reports, 10, 4449.</Citation></Reference><Reference><Citation>Martinez-Gonzalez L, Rojas-Prats E, Liachko N, Gil C, C. KB, Martin-Requero A, &amp; Martinez A (2019). TDP-43 modulation by CDC7 inhibitors as a therapeutic strategy for amyotrophic lateral sclerosis. International Workshop on ALS New genes, new treatments, new hopes.</Citation></Reference><Reference><Citation>Mattson, M. P., &amp; Camandola, S. (2001). NF-&#x3ba;B in neuronal plasticity and neurodegenerative disorders. The Journal of Clinical Investigation, 107, 247-254. https://doi.org/10.1172/JCI11916</Citation></Reference><Reference><Citation>Meyerowitz, J., Parker, S. J., Vella, L. J., Ng, D., Price, K. A., Liddell, J. R., &#x2026; White, A. R. (2011). C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Molecular Neurodegeneration, 6, 57. https://doi.org/10.1186/1750-1326-6-57</Citation></Reference><Reference><Citation>Miduturu, C. V., Deng, X., Kwiatkowski, N., Yang, W., Brault, L., Filippakopoulos, P., &#x2026; Gray, N. S. (2011). High-throughput kinase profiling: A more efficient approach toward the discovery of new kinase inhibitors. Chemistry &amp; Biology, 18, 868-879. https://doi.org/10.1016/j.chembiol.2011.05.010</Citation></Reference><Reference><Citation>Montagnoli, A., Moll, J., &amp; Colotta, F. (2010). Targeting cell division cycle 7 kinase: A new approach for cancer therapy. Clinical Cancer Research, 16, 4503-4508. https://doi.org/10.1158/1078-0432.CCR-10-0185</Citation></Reference><Reference><Citation>Mora, J. S., Genge, A., Chio, A., Estol, C. J., Chaverri, D., Hernandez, M., &#x2026; Ab10015 Study G. (2020). Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener, 21, 5-14. https://doi.org/10.1080/21678421.2019.1632346</Citation></Reference><Reference><Citation>Morrison, D. K. (2012). MAP kinase pathways. Cold Spring Harbor Perspectives in Biology, 4. https://doi.org/10.1101/cshperspect.a011254</Citation></Reference><Reference><Citation>Mukhopadhyay, S., Frias, M. A., Chatterjee, A., Yellen, P., &amp; Foster, D. A. (2016). The enigma of papamycin dosage. Molecular Cancer Therapeutics, 15, 347-353. https://doi.org/10.1158/1535-7163.MCT-15-0720</Citation></Reference><Reference><Citation>Mutoh, T., Sobue, G., Hamano, T., Kuriyama, M., Hirayama, M., Yamamoto, M., &amp; Mitsuma, T. (2000). Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochemical Research, 25, 239-245. https://doi.org/10.1023/A:1007575504321</Citation></Reference><Reference><Citation>Neumann, M., Kwong, L. K., Lee, E. B., Kremmer, E., Flatley, A., Xu, Y., &#x2026; Lee, V. M. (2009). Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathologica, 117, 137-149. https://doi.org/10.1007/s00401-008-0477-9</Citation></Reference><Reference><Citation>Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., &#x2026; Lee, V. M. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133. https://doi.org/10.1126/science.1134108</Citation></Reference><Reference><Citation>Neuzillet, C., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., &amp; Raymond, E. (2014). MEK in cancer and cancer therapy. Pharmacology &amp; Therapeutics, 141, 160-171.</Citation></Reference><Reference><Citation>Nishitoh, H., Kadowaki, H., Nagai, A., Maruyama, T., Yokota, T., Fukutomi, H., &#x2026; Ichijo, H. (2008). ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes &amp; Development, 22, 1451-1464. https://doi.org/10.1101/gad.1640108</Citation></Reference><Reference><Citation>Nozal V, Ben&#xed;tez-Fern&#xe1;ndez R, Mart&#xed;nez-Gonz&#xe1;lez L, P&#xe9;rez DI, Gil C, &amp; Mart&#xed;nez A (2018). TTBK1 inhibitors: A novel multifactorial approach for the treatment of AD and ALS. 10th Summer School on Medicines S&#xe3;o Paulo School of Advanced Science.</Citation></Reference><Reference><Citation>Nozal, V., &amp; Martinez, A. (2019). Tau tubulin kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. European Journal of Medicinal Chemistry, 161, 39-47. https://doi.org/10.1016/j.ejmech.2018.10.030</Citation></Reference><Reference><Citation>Oetjen, E., &amp; Lemcke, T. (2016). Dual leucine zipper kinase (MAP 3K12) modulators: A patent review (2010-2015). Expert Opinion on Therapeutic Patents, 26, 607-616.</Citation></Reference><Reference><Citation>Palomo, V., Perez, D. I., Gil, C., &amp; Martinez, A. (2011). The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. Current Medicinal Chemistry, 18, 3028-3034. https://doi.org/10.2174/092986711796391697</Citation></Reference><Reference><Citation>Palomo, V., Tosat-Bitrian, C., Nozal, V., Nagaraj, S., Martin-Requero, A., &amp; Martinez, A. (2019). TDP-43: A key therapeutic target beyond amyotrophic lateral sclerosis. ACS Chemical Neuroscience, 10, 1183-1196. https://doi.org/10.1021/acschemneuro.9b00026</Citation></Reference><Reference><Citation>Patel, S., Harris, S. F., Gibbons, P., Deshmukh, G., Gustafson, A., Kellar, T., &#x2026; Lewcock, J. W. (2015). Scaffold-hopping and structure-based discovery of potent, selective, and brain penetrant N-(1H-pyrazol-3-yl)pyridin-2-amine inhibitors of dual leucine Zzpper kinase (DLK, MAP 3K12). Journal of Medicinal Chemistry, 58, 8182-8199.</Citation></Reference><Reference><Citation>Peel, A. L. (2004). PKR activation in neurodegenerative disease. Journal of Neuropathology and Experimental Neurology, 63, 97-105. https://doi.org/10.1093/jnen/63.2.97</Citation></Reference><Reference><Citation>Piepers, S., Veldink, J. H., de Jong, S. W., van der Tweel, I., van der Pol, W. L., Uijtendaal, E. V., &#x2026; van den Berg, L. H. (2009). Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Annals of Neurology, 66, 227-234. https://doi.org/10.1002/ana.21620</Citation></Reference><Reference><Citation>Pignataro, G., Capone, D., Polichetti, G., Vinciguerra, A., Gentile, A., Di Renzo, G., &amp; Annunziato, L. (2011). Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: Current and emerging therapeutic options. Current Opinion in Pharmacology, 11, 378-394. https://doi.org/10.1016/j.coph.2011.05.003</Citation></Reference><Reference><Citation>Pizzasegola, C., Caron, I., Daleno, C., Ronchi, A., Minoia, C., Carri, M. T., &amp; Bendotti, C. (2009). Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotrophic Lateral Sclerosis, 10, 221-228. https://doi.org/10.1080/17482960902803440</Citation></Reference><Reference><Citation>Posa, D., Martinez-Gonzalez, L., Bartolome, F., Nagaraj, S., Porras, G., Martinez, A., &amp; Martin-Requero, A. (2019). Recapitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients. Molecular Neurobiology, 56, 2424-2432. https://doi.org/10.1007/s12035-018-1249-8</Citation></Reference><Reference><Citation>Pradhan, J., Noakes, P. G., &amp; Bellingham, M. C. (2019). The role of altered BDNF/TrkB signaling in amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 13, 368.</Citation></Reference><Reference><Citation>Roskoski, R. Jr. (2020). Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacological Research, 152, 104609. https://doi.org/10.1016/j.phrs.2019.104609</Citation></Reference><Reference><Citation>Ryu, H. H., Jun, M. H., Min, K. J., Jang, D. J., Lee, Y. S., Kim, H. K., &amp; Lee, J. A. (2014). Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons. Neurobiology of Aging, 35, 2822-2831. https://doi.org/10.1016/j.neurobiolaging.2014.07.026</Citation></Reference><Reference><Citation>Salado, I. G., Redondo, M., Bello, M. L., Perez, C., Liachko, N. F., Kraemer, B. C., &#x2026; Perez, D. I. (2014). Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. Journal of Medicinal Chemistry, 57, 2755-2772. https://doi.org/10.1021/jm500065f</Citation></Reference><Reference><Citation>Sama, R. R., Fallini, C., Gatto, R., McKeon, J. E., Song, Y., Rotunno, M. S., &#x2026; Bosco, D. A. (2017). ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation. Scientific Reports, 7, 115. https://doi.org/10.1038/s41598-017-00091-1</Citation></Reference><Reference><Citation>Sato, S., Cerny, R. L., Buescher, J. L., &amp; Ikezu, T. (2006). Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. Journal of Neurochemistry, 98, 1573-1584. https://doi.org/10.1111/j.1471-4159.2006.04059.x</Citation></Reference><Reference><Citation>Schittek, B., &amp; Sinnberg, T. (2014). Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. Molecular Cancer, 13, 231. https://doi.org/10.1186/1476-4598-13-231</Citation></Reference><Reference><Citation>Simmons, D. L. (2013). Targeting kinases: A new approach to treating inflammatory rheumatic diseases. Current Opinion in Pharmacology, 13, 426-434. https://doi.org/10.1016/j.coph.2013.02.008</Citation></Reference><Reference><Citation>Siu, M., Sengupta Ghosh, A., &amp; Lewcock, J. W. (2018). Dual leucine zipper kinase inhibitors for the treatment of neurodegeneration. Journal of Medicinal Chemistry, 61, 8078-8087.</Citation></Reference><Reference><Citation>Sreedharan, J., Neukomm, L. J., Brown, R. H. Jr., &amp; Freeman, M. R. (2015). Age-dependent TDP-43-mediated motor neuron degeneration requires GSK3, hat-trick, and xmas-2. Current Biology, 25, 2130-2136. https://doi.org/10.1016/j.cub.2015.06.045</Citation></Reference><Reference><Citation>Strong, M. J., Kesavapany, S., &amp; Pant, H. C. (2005). The pathobiology of amyotrophic lateral sclerosis: A proteinopathy? Journal of Neuropathology and Experimental Neurology, 64, 649-664. https://doi.org/10.1097/01.jnen.0000173889.71434.ea</Citation></Reference><Reference><Citation>Sugai, F., Yamamoto, Y., Miyaguchi, K., Zhou, Z., Sumi, H., Hamasaki, T., &#x2026; Sakoda, S. (2004). Benefit of valproic acid in suppressing disease progression of ALS model mice. The European Journal of Neuroscience, 20, 3179-3183.</Citation></Reference><Reference><Citation>Sulzmaier, F. J., Jean, C., &amp; Schlaepfer, D. D. (2014). FAK in cancer: Mechanistic findings and clinical applications. Nature Reviews. Cancer, 14, 598-610. https://doi.org/10.1038/nrc3792</Citation></Reference><Reference><Citation>Sun, J., Mu, Y., Jiang, Y., Song, R., Yi, J., Zhou, J., &#x2026; Xu, X. (2018). Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates. Cell Death &amp; Disease, 9, 407. https://doi.org/10.1038/s41419-018-0441-0</Citation></Reference><Reference><Citation>Sun, J., &amp; Nan, G. (2017). The extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target (Review). International Journal of Molecular Medicine, 39, 1338-1346.</Citation></Reference><Reference><Citation>Suzuki, H., &amp; Matsuoka, M. (2013). The JNK/c-Jun signaling axis contributes to the TDP-43-induced cell death. Molecular and Cellular Biochemistry, 372, 241-248.</Citation></Reference><Reference><Citation>Takata, M., Tanaka, H., Kimura, M., Nagahara, Y., Tanaka, K., Kawasaki, K., &#x2026; Hara, H. (2013). Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. British Journal of Pharmacology, 170, 341-351. https://doi.org/10.1111/bph.12277</Citation></Reference><Reference><Citation>Taniguchi, J., Seki, C., Takuwa, H., Kawaguchi, H., Ikoma, Y., Fujinaga, M., &#x2026; Ito, H. (2014). Evaluation of Rho-kinase activity in mice brain using N-[11C]methyl-hydroxyfasudil with positron emission tomography. Molecular Imaging and Biology, 16, 395-402. https://doi.org/10.1007/s11307-013-0695-y</Citation></Reference><Reference><Citation>Taylor, L. M., McMillan, P. J., Liachko, N. F., Strovas, T. J., Ghetti, B., Bird, T. D., &#x2026; Kraemer, B. C. (2018). Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Molecular Neurodegeneration, 13, 7. https://doi.org/10.1186/s13024-018-0237-9</Citation></Reference><Reference><Citation>T&#xf6;nges, L., G&#xfc;nther, R., Suhr, M., Jansen, J., Balck, A., Saal, K. A., &#x2026; Lingor, P. (2014). Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia, 62, 217-232.</Citation></Reference><Reference><Citation>Trias, E., Ibarburu, S., Barreto-Nunez, R., Babdor, J., Maciel, T. T., Guillo, M., &#x2026; Barbeito, L. (2016). Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. Journal of Neuroinflammation, 13, 177. https://doi.org/10.1186/s12974-016-0620-9</Citation></Reference><Reference><Citation>Trias, E., King, P. H., Si, Y., Kwon, Y., Varela, V., Ibarburu, S., &#x2026; Barbeito, L. (2018). Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight, 3. https://doi.org/10.1172/jci.insight.123249</Citation></Reference><Reference><Citation>Vaca, G., Mart&#xed;nez-Gonz&#xe1;lez, L., Fern&#xe1;ndez, A., Rojas-Prats, E., Porras, G., Cuevas, E. P., &#x2026; Martin-Requero, A. (2020). Therapeutic potential of novel cell division cycle kinase 7 inhibitors on TDP-43-related pathogenesis such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Journal of Neurochemistry. https://doi.org/10.1111/jnc.15118</Citation></Reference><Reference><Citation>Van Hoecke, A., Schoonaert, L., Lemmens, R., Timmers, M., Staats, K. A., Laird, A. S., &#x2026; Robberecht, W. (2012). EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nature Medicine, 18, 1418-1422.</Citation></Reference><Reference><Citation>Vanotti, E., Amici, R., Bargiotti, A., Berthelsen, J., Bosotti, R., Ciavolella, A., &#x2026; Santocanale, C. (2008). CDC7 kinase inhibitors: Pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. Journal of Medicinal Chemistry, 51, 487-501. https://doi.org/10.1021/jm700956r</Citation></Reference><Reference><Citation>Verstraete, E., Veldink, J. H., Huisman, M. H., Draak, T., Uijtendaal, E. V., van der Kooi, A. J., &#x2026; van den Berg, L. H. (2012). Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomised sequential trial. Journal of Neurology, Neurosurgery, and Psychiatry, 83, 557-564.</Citation></Reference><Reference><Citation>Villanueva, M. T. (2017). Neurodegenerative disease: DLK zips across neurodegeneration. Nature Reviews. Drug Discovery, 16, 678-679. https://doi.org/10.1038/nrd.2017.180</Citation></Reference><Reference><Citation>Wang, I. F., Guo, B. S., Liu, Y. C., Wu, C. C., Yang, C. H., Tsai, K. J., &amp; Shen, C. K. (2012). Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proceedings of the National Academy of Sciences of the United States of America, 109, 15024-15029. https://doi.org/10.1073/pnas.1206362109</Citation></Reference><Reference><Citation>Watts, M. E., Wu, C., &amp; Rubin, L. L. (2019). Suppression of MAP 4K4 signaling ameliorates motor neuron degeneration in amyotrophic lateral sclerosis-molecular studies toward new therapeutics. J Exp Neurosci, 13, 1179069519862798.</Citation></Reference><Reference><Citation>Wheaton, M. W., Salamone, A. R., Mosnik, D. M., McDonald, R. O., Appel, S. H., Schmolck, H. I., &#x2026; Schulz, P. E. (2007). Cognitive impairment in familial ALS. Neurology, 69, 1411-1417. https://doi.org/10.1212/01.wnl.0000277422.11236.2c</Citation></Reference><Reference><Citation>Wu, B., De, S. K., Kulinich, A., Salem, A. F., Koeppen, J., Wang, R., &#x2026; Pellecchia, M. (2017). Potent and selective EphA4 agonists for the treatment of ALS. Cell Chemical Biology, 24, 293-305. https://doi.org/10.1016/j.chembiol.2017.01.006</Citation></Reference><Reference><Citation>Wu, C., Watts, M. E., &amp; Rubin, L. L. (2019). MAP 4K4 activation mediates motor neuron degeneration in amyotrophic lateral sclerosis. Cell Reports, 26, 1143-1156. https://doi.org/10.1016/j.celrep.2019.01.019</Citation></Reference><Reference><Citation>Wu, P., Clausen, M. H., &amp; Nielsen, T. E. (2015). Allosteric small-molecule kinase inhibitors. Pharmacology &amp; Therapeutics, 156, 59-68. https://doi.org/10.1016/j.pharmthera.2015.10.002</Citation></Reference><Reference><Citation>Xia, Q., Hu, Q., Wang, H., Yang, H., Gao, F., Ren, H., &#x2026; Wang, G. (2015). Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. Cell Death &amp; Disease, 6, e1702. https://doi.org/10.1038/cddis.2015.69</Citation></Reference><Reference><Citation>Xu, D., Jin, T., Zhu, H., Chen, H., Ofengeim, D., Zou, C., &#x2026; Yuan, J. (2018). TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell, 174, 1477-1491 e1419.</Citation></Reference><Reference><Citation>Xue, Y., Wan, P. T., Hillertz, P., Schweikart, F., Zhao, Y., Wissler, L., &amp; Dekker, N. (2013). X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors. ChemMedChem, 8, 1846-1854. https://doi.org/10.1002/cmdc.201300274</Citation></Reference><Reference><Citation>Yang, W., Leystra-Lantz, C., &amp; Strong, M. J. (2008). Upregulation of GSK3&#x3b2; expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Research, 1196, 131-139. https://doi.org/10.1016/j.brainres.2007.12.031</Citation></Reference><Reference><Citation>Yang, Y. M., Gupta, S. K., Kim, K. J., Powers, B. E., Cerqueira, A., Wainger, B. J., &#x2026; Rubin, L. L. (2013). A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell, 12, 713-726.</Citation></Reference><Reference><Citation>Yanpallewar, S. U., Barrick, C. A., Buckley, H., Becker, J., &amp; Tessarollo, L. (2012). Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS ONE, 7, e39946.</Citation></Reference><Reference><Citation>Yarza, R., Vela, S., Solas, M., &amp; Ramirez, M. J. (2015). c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer's disease. Frontiers in Pharmacology, 6, 321.</Citation></Reference><Reference><Citation>Zhang, X., Li, L., Chen, S., Yang, D., Wang, Y., Zhang, X., &#x2026; Le, W. (2011). Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy, 7, 412-425. https://doi.org/10.4161/auto.7.4.14541</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>